bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S4 from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Correlation of nstringRS between different types of tumor samples (Section, core, Ki67, and PR)
Supplementary Table 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Relative proportion and survival analyses of all possible combination groups accounting for LDH, pattern of visceral metastasis, RLC and REC
Revised supplemental figures from Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
Authors: Ben-Batalla Isabel , Erdmann Robert , Jørgensen Heather , Mitchell Rebecca , Ernst Thomas , von Amsberg Gunhild , Schafhausen Philippe , Velthaus Janna L. , Rankin Stephen , Clark Richard E. , Koschmieder Steffen , Schultze Alexander , Mitra Subir , Vandenberghe Peter , Brümmendorf Tim H. , Carmeliet Peter , Hochhaus Andreas , Pantel Klaus , Bokemeyer Carsten , Helgason G. Vignir , Holyoake Tessa L. , Loges Sonja
Published: April 2023

Figure S1. Inhibition of Axl by shRNA. Figure S2. Assessment of half maximal inhibitory concentration (IC50) for BGB324 in human CD34+ cells from healthy donors. Figure S3. Treatment with BGB324 increased apoptosis and decreased proliferation of CML cell lines. Figure S4. Reduction of BCR-ABL and Crkl phosphorylation by imatinib. Figure S5. Treatment with imatinib and BGB324 does not induce an additive inhibitory effect on phosphorylation of Erk and Akt. Figure S6. BCR-ABL and Crkl phosphorylation are not affected by imatinib or BGB324 in KCL-22 T315I mutated cells. Figure S7. Colony forming assay using primary CD34+ cells isolated from healthy donors treated for 72 h with 1, 3 or 5 μM of BGB324 (n=2). Figure S8. BGB324 increases apoptosis of primary CML cells.
Supplementary Figure 1 from Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition
Authors: Sanmartín Elena , Muñoz Lisandra , Piqueras Marta , Sirerol J. Antoni , Berlanga Pablo , Cañete Adela , Castel Victoria , Font de Mora Jaime
Published: April 2023

Molecular karyotype in circos plots of patients with 11q deletion. Each patient code is indicated in the middle of each plot. Allele peacks (inner plots) and weigthed Log2ratio (middle plots) information were obtained from Affymetrix software ChAS and further used to generate circus plots.
Supplementary Information text from STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma
Authors: Otaka Yukihiro , Rokudai Susumu , Kaira Kyoichi , Fujieda Michiru , Horikoshi Ikuko , Iwakawa-Kawabata Reika , Yoshiyama Shinji , Yokobori Takehiko , Ohtaki Yoichi , Shimizu Kimihiro , Oyama Tetsunari , Tamura Jun'ichi , Prives Carol , Nishiyama Masahiko
Published: April 2023

Supplementary Information and Supplementary Figures Legends
Supplemental Figure S4 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Figure S4: Exogenous ANXA1 does not confer trastuzumab resistance
Supplementary Table S2 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Characteristics of patients who received prior treatment with BRAF and/or MEK inhibitors (N=10). A table summarizing the characteristics, PTEN status and best response in patients who previously received BRAF and/or MEK inhibitors (N=10).
Supplementary Figure S4 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas
Authors: Remacha Laura , Comino-Méndez Iñaki , Richter Susan , Contreras Laura , Currás-Freixes María , Pita Guillermo , Letón Rocío , Galarreta Antonio , Torres-Pérez Rafael , Honrado Emiliano , Jiménez Scherezade , Maestre Lorena , Moran Sebastian , Esteller Manel , Satrústegui Jorgina , Eisenhofer Graeme , Robledo Mercedes , Cascón Alberto
Published: April 2023

DNA methylation (M-values) of the CpG island probes located within six PCC/PGL susceptibility genes encoding Krebs cycle enzymes (SDHA, SDHAF2, SDHB, SDHD, FH, and MDH2) in the 11 analyzed tumors, compared to in vitro methylated DNA (IVD).
Table S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

Independent reader data and inter-reader agreement for the MRI features of the 125 LGGs from the TCGA/TCIA database.
AZD1775 MS Supplementary Materials from Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach
Authors: Li Jing , Wu Jianmei , Bao Xun , Honea Norissa , Xie Youming , Kim Seongho , Sparreboom Alex , Sanai Nader
Published: April 2023

SUPPLEMENTARY METHODS Supplementary Figure 1 Overall metabolic kinetics of AZD1775 in human liver and intestinal microsomes (HLM and HIM). Supplementary Figure 2 PBPK model simulations showing the impact of BBB integrity (i.e., PSB), transporter activity (i.e., CLefflux,vivo and CLuptake,vivo), and drug binding to brain tissues (i.e., fu,br) on the extent of AZD1775 BBB penetration (assessed by Kp,uu) and the rate of penetration (assessed by Tmax,br).
Supplementary tables from Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
Authors: Quispel-Janssen Josine M. , Badhai Jitendra , Schunselaar Laurel , Price Stacey , Brammeld Jonathan , Iorio Francesco , Kolluri Krishna , Garnett Matthew , Berns Anton , Baas Paul , McDermott Ultan , Neefjes Jacques , Alifrangis Constantine
Published: April 2023

Supplementary Table , tab 1 List of compounds used in the chemical inhibitor screen. Supplementary table ,tab 2 SPIA pathway analysis performed highlighting significantly upregulated/downregulated pathways between BAP1 mutant and BAP1 wild type lines. Supplementary table, tab 3. GEO data analysis of 40 BAP1wt vs 11 BAP1mt mesothelioma tumours showing fold change in mRNA expression.
Supplementary table 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Patient characteristics
Supplemental Table 1 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Table 1: Overall immune response detected in the peripheral blood by route of vaccine administration and ER status
Supplemental Tables and Figures from Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Authors: Rugo Hope S. , Cortes Javier , Awada Ahmad , O'Shaughnessy Joyce , Twelves Chris , Im Seock-Ah , Hannah Alison , Lu Lin , Sy Sherwin , Caygill Katie , Zajchowski Deborah A. , Davis Darren W. , Tagliaferri Mary , Hoch Ute , Perez Edith A.
Published: April 2023

Supplemental Tables and Figures
Supplementary Figure 3 from Neoadjuvant Enzalutamide Prior to Prostatectomy
Authors: Montgomery Bruce , Tretiakova Maria S. , Joshua Anthony M. , Gleave Martin E. , Fleshner Neil , Bubley Glenn J. , Mostaghel Elahe A. , Chi Kim N. , Lin Daniel W. , Sanda Martin , Novotny William , Wu Kenneth , Kantoff Philip W. , Marck Brett T. , Plymate Stephen , Balk Steven P. , Nelson Peter S. , Matsumoto Alvin M. , Lis Rosina T. , Kibel Adam , Haas Gabriel P. , Krivoshik Andrew , Hannah Alison , Taplin Mary-Ellen
Published: April 2023

Figure S3. Change in serum androgen levels after enza or enza/dut/LHRHa. Box plots of serum androgens for each cohort at initiation of therapy (day 0) and at prostatectomy (day 180) are depicted for each treatment arm. Levels of (A) pregnenolone, (B) progesterone, (C) DHEA, (D) AED, (E) testosterone, and (F) DHT were measured by mass spectroscopy. P values were calculated using the nonparametric Mann-Whitney test. Limits of quantification were 0.005 ng/mL for AED, progesterone and testosterone, 0.001 ng/mL for DHT and pregnenolone, and 0.15 ng/mL for DHEA.
Figure S3 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S3. Sphere colony shapes. HEY1 expression in si-HEY1 cells and NOTCH4 expressions in sh-NOTCH4 cells
sup 1 from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental Figure 1. A) Left panel: Visualization of the miRNA profile of normal pancreas samples (n=3 control). Right panel: Visualization of the miRNA profile of PDAC PDX tumor samples (n=27 cases). Relative expression is shown as mean of fluorescence (MFI). miRNAs profiling was done through Firefly Circulating miRNA Assay and normalized using two miRNAs that are not significantly deregulated between all samples miR-22-3p and miR-30b-5p defined by the geNorm-like 37 algorithm. B) Visualization of miRNA profiles of PDAC cell lines (n=4), PDAC 3Dmodel (n=2) and Patient-derived-organoid (PDO 286 and PDO 281) compared to normal pancreatic cell and organoid (n=2 control). miRNAs profiling was done via Firefly Circulating miRNA Assay and normalized using miR-181b-5p, miR-103-3p, miR-30b-5p defined by the geNorm-like algorithm. Normalized miRNA signal intensities are presented as fold-change (log10 of the ratio between a probe value to the average of all the other samples for that probe). Green represents highly expressed miRNAs and red represents lowly expressed miRNAs.
Sup. Figure 2: KM12SM-ER cells were resistant to treatment with 15mg/kg and 30mg/kg entrectinib in the brain metastasis-mimicking model. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

KM12SM-ER cells were inoculated into the brain of SHO mice. The mice were treated daily with or without entrectinib (15 mg/kg or 30mg/kg) from day 8 to day 17. Mean {plus minus} SE of total flux are shown in the left panel. Representative pictures were shown in the right panel.
Supplemental Figure 4 from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Jain Preetesh , Keating Michael J. , Wierda William G. , Sivina Mariela , Thompson Philip A. , Ferrajoli Alessandra , Estrov Zeev , Kantarjian Hagop , O'Brien Susan , Burger Jan A.
Published: April 2023

Changes in absolute T cell numbers on treatment with ibrutinib and rituximab up to 3 years.
Supplementary materials and methods from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Supplementary materials and methods
Supplementary Tables from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Table S1 Mean density values of crystal violet staining of 16 melanoma cell lines treated with 6-thio-dG and PLX4720. Table S2 RNA-seq data related to A375 cells treated with 6-thio-dG. Table S3 RNA-seq data related to A375 cells treated with BIBR 1532. Table S4 Apoptotic index and ssGSEA scores of 11 gene sets in 18 CCLE melanoma cell lines. Table S5 RPPA data related to A375 cells treated with 6-thio-dG. Table S6 Mean density values of crystal violet staining of 6 therapy-resistant melanoma cell lines treated with 6-thio-dG. Table S7 RPPA data related to the comparison between LOX-IMVI parental and BR cells. Table S8 RPPA data related to LOX-IMVI parental cells treated with 6-thio-dG. Table S9 RPPA data related to LOX-IMVI BR cells treated with 6-thio-dG. Table S10 RPPA data related to LOX-IMVI BR xenografts treated with 6-thio-dG. Table S11 The clinical information from patients with metastatic melanoma treated with immunotherapies.
Supplementary Table 1 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Table 1. Treatment exposures and TP53 Variant status in the Validation cohort Tumor, TP53 variant status (G215C, A639G), and treatment exposure details are shown for each validation sample (VS).
Supplementary Files from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary File 1. SNVs for Patient 1's SMN;Supplementary File 2. SNVs for Patient 2's SMN;Supplementary File 3. List of dinucleotide substitutions;Supplementary File 4. TP53 germline sequencing primers
Supplementary Figure 5 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Figure 5:Germline TP53 variants in the validation cohort Sanger sequencing-derived electropherograms displaying the germline variant in Exon 4 are shown.
Supplemental Figure 2 from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Sensitivity analysis demonstrating optimal left vs right cut-point to maximize prognostic differences based on side in metastatic colorectal cancer. Sub-caption: Numbers in figure represent the hazard ratio followed by the 95% confidence interval within square brackets. The hazard ratio estimate occurs at the location used to divide left from right in each sensitivity analysis. For example, if the division between right and left occurs between the hepatic flexure and transverse colon, the hazard ratio estimate will be placed on the graph half way between the hepatic flexure and transverse colon (ie. 1.66).
Supplementary Data from Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma
Authors: Sun Yun-Fan , Guo Wei , Xu Yang , Shi Yin-Hong , Gong Zi-Jun , Ji Yuan , Du Min , Zhang Xin , Hu Bo , Huang Ao , Chen George G. , Lai Paul B.S. , Cao Ya , Qiu Shuang-Jian , Zhou Jian , Yang Xin-Rong , Fan Jia
Published: April 2023

Figure S1. Dynamic change of the clustering status of circulating tumor cells (CTCs) along their circulating route. Figure S2. Variation of circulating tumor cell (CTC) clustering status between primary hepatocellular carcinoma (HCC) efferent and afferent micovessels. Example of circulating tumor microemboli (CTM) detected in microscopic hepatic vein (mHV, efferent vessel) and singular CTCs in microscopic hepatic artery (mHA, afferent vessel) stained for epithelial (E) and mesenchymal (M) markers. E-cad = E-cadherin, red; CK = cytokeratin, brown; vit = vimentin, brown. Scale bar: original magnification, 100μm; inserts, 25 μm. Figure S3. Determination of epithelial-mesenchymal transition (EMT)-related marker expression on hepatocellular carcinoma (HCC) cell lines. Figure S4. Circulating tumor cells (CTCs) isolated using the CELLSEARCH® system were verified by confocal microscopy. Figure S5. Scatter plots showing the comparison of the cell counts of each EMT-related CTC phenotype from five vascular sites, including HV, PA, PV, IHIVC, and PoV (*P<0.05, **P<0.01, n.s. = not significant, Wilcoxon signed-rank test). Figure S6. The proportional distribution of EMT-related CTC phenotypes based on E and M staining at five key vascular sites. Figure S7. Receiver operating characteristic (ROC) curve analysis for range of circulating tumor cell (CTC) cutoff values. Table S1. Anatomic distribution of CTCs and CTMs Table S2 Pairwise comparison of CTC and CTM detected at different gross vascular sites Table S3. The correlation between primary tumor EMT status and CTC EMT status detected in gross and microscopic hepatic vein
Figure S7 from Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Schunselaar Laurel M. , Quispel-Janssen Josine M.M.F. , Kim Yongsoo , Alifrangis Constantine , Zwart Wilbert , Baas Paul , Neefjes Jacques
Published: April 2023

Fig. S7. Dose-response curves and clinical responses. (A) Dose-response curves of primary tumor cultures performed for patient 4-7, 9 and 10. The chemotherapeutic agent that was given to the patient is depicted in color the rest of the screened chemotherapeutics is depicted with a gray line and colored dots. (B) CT-scans of patient 4-7, 9 and 10 before and after treatment with the drugs selected based on the in vitro drug screen. Response evaluation was done using modified RECIST for mesothelioma. Colored boxes around CT-scans indicate in vitro response prediction before treatment and actual response after treatment. Green: partial response, yellow: stable disease, red: progressive disease. Tumor-rinds are indicated by red line.
Suppl. Figure 5 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

Gating for three representative patients
Supplementary Tables from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Authors: Chen Ying , Camacho Sandra Catalina , Silvers Thomas R. , Razak Albiruni R.A. , Gabrail Nashat Y. , Gerecitano John F. , Kalir Eva , Pereira Elena , Evans Brad R. , Ramus Susan J. , Huang Fei , Priedigkeit Nolan , Rodriguez Estefania , Donovan Michael , Khan Faisal , Kalir Tamara , Sebra Robert , Uzilov Andrew , Chen Rong , Sinha Rileen , Halpert Richard , Billaud Jean-Noel , Shacham Sharon , McCauley Dilara , Landesman Yosef , Rashal Tami , Kauffman Michael , Mirza Mansoor R. , Mau-Sørensen Morten , Dottino Peter , Martignetti John A.
Published: April 2023

Supplementary Table 1. cBIO data for XPO1 overexpression and association with survival. Supplementary Table 2. Clinical features of patient samples in TMA. Supplementary Table 3. Clinicopathologic features for patient-derived tumor cell lines.
Supplementary Table 2 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

Associations between p62 protein expression and clinicopathological parameters
Supplementary Table S1 from Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Krumbholz Manuela , Hellberg Julia , Steif Benedikt , Bäuerle Tobias , Gillmann Clarissa , Fritscher Torsten , Agaimy Abbas , Frey Benjamin , Juengert Joerg , Wardelmann Eva , Hartmann Wolfgang , Juergens Heribert , Dirksen Uta , Metzler Markus
Published: April 2023

Sequences of primers used in nested multiplex PCR assays
Supplementary Figure 4 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Authors: Wang Dongsheng , Qian Guoqing , Zhang Hongzheng , Magliocca Kelly R. , Nannapaneni Sreenivas , Amin A.R.M. Ruhul , Rossi Michael , Patel Mihir , El-Deiry Mark , Wadsworth J. Trad , Chen Zhengjia , Khuri Fadlo R. , Shin Dong M. , Saba Nabil F. , Chen Zhuo G.
Published: April 2023

PDX tumor growth of patient 3 under the treatment of indicated drug
Supplementary Table 3 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Authors: McCoach Caroline E. , Le Anh T. , Gowan Katherine , Jones Kenneth , Schubert Laura , Doak Andrea , Estrada-Bernal Adriana , Davies Kurtis D. , Merrick Daniel T. , Bunn Paul A. , Purcell W. Tom , Dziadziuszko Rafal , Varella-Garcia Marileila , Aisner Dara L. , Camidge D. Ross , Doebele Robert C.
Published: April 2023

ALK and ROS1 patient specific data
Supplementary movie 2 from Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis
Authors: Tzeng Hong-Tai , Tsai Chung-Han , Yen Yi-Ting , Cheng Hung-Chi , Chen Yi-Chieh , Pu Shih-Wen , Wang Yu-Shiuan , Shan Yan-Shen , Tseng Yau-Lin , Su Wu-Chou , Lai Wu-Wei , Wu Li-Wha , Wang Yi-Ching
Published: April 2023

Time-lapse movie of TIRF images of Rab37-CE81T cells expressing GFP-tagged TSP1.
Supplementary information from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

Legends to Supplementary Figures and Dataset
Figure S2 from Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Authors: Liu Liang , Yang Lin , Yan Wei , Zhai Jing , Pizzo Donald P. , Chu Peiguo , Chin Andrew R. , Shen Meng , Dong Chuan , Ruan Xianhui , Ren Xiubao , Somlo George , Wang Shizhen Emily
Published: April 2023

Figure S2 shows the complete blood counts in chemotherapy-treated C57BL/6 mice
Supplementary Figure 1 from Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Authors: Bellone Stefania , Buza Natalia , Choi Jungmin , Zammataro Luca , Gay Laurie , Elvin Julia , Rimm David L. , Liu Yuting , Ratner Elena S. , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Supplementary Figure 1. Structure and breakpoint DNA sequence of CD274 (lower case) and PLGRKT 32bp insertion (upper case) in the high grade ovarian carcinoma.
Supplemental Text_PTEN_MET_IHC methods from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

PTEN and MET IHC methods
Supplementary Information from Role of Host miRNA Hsa-miR-139-3p in HPV-16–Induced Carcinomas
Authors: Sannigrahi M.K. , Sharma Rajni , Singh Varinder , Panda Naresh K. , Rattan Vidya , Khullar Madhu
Published: April 2023

Supplementary Information Data
Supplementary Figure 6 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Authors: Slaney Clare Y. , von Scheidt Bianca , Davenport Alexander J. , Beavis Paul A. , Westwood Jennifer A. , Mardiana Sherly , Tscharke David C. , Ellis Sarah , Prince H. Miles , Trapani Joseph A. , Johnstone Ricky W. , Smyth Mark J. , Teng Michele W. , Ali Aesha , Yu Zhiya , Rosenberg Steven A. , Restifo Nicholas P. , Neeson Paul , Darcy Phillip K. , Kershaw Michael H.
Published: April 2023

Cytokines present in serum of ACTIV-treated mice.
Supplementary File S1 from Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Gupta Santosh , Li Jing , Kemeny Gabor , Bitting Rhonda L. , Beaver Joshua , Somarelli Jason A. , Ware Kathryn E. , Gregory Simon , Armstrong Andrew J.
Published: April 2023

File S1: List of non-redundant copy number-altered genes from > 50% (more than 4 of 7) of cases from AR-amplified samples used for IPA.
Supplementary Figure 1 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Authors: Slaney Clare Y. , von Scheidt Bianca , Davenport Alexander J. , Beavis Paul A. , Westwood Jennifer A. , Mardiana Sherly , Tscharke David C. , Ellis Sarah , Prince H. Miles , Trapani Joseph A. , Johnstone Ricky W. , Smyth Mark J. , Teng Michele W. , Ali Aesha , Yu Zhiya , Rosenberg Steven A. , Restifo Nicholas P. , Neeson Paul , Darcy Phillip K. , Kershaw Michael H.
Published: April 2023

Dual-specific T cells respond against both gp100 and Her2.
Allan Lipton_Conflict of Interest Form from Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Authors: Lipton Allan , Smith Matthew R. , Fizazi Karim , Stopeck Alison T. , Henry David , Brown Janet E. , Shore Neal D. , Saad Fred , Spencer Andrew , Zhu Li , Warner Douglas J.
Published: April 2023

Conflict of Interest Form
Figure S5 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

NHS-muIL12 and avelumab combination treatment enhanced the necrotic fraction in EMT-6 tumors.
Figure S3 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

NHS-muIL12 and avelumab combination treatment increased p15E-reactive cells in an ELISpot assay.
Supplementary Table S3 from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Authors: Montfort Anne , Pearce Oliver , Maniati Eleni , Vincent Benjamin G. , Bixby Lisa , Böhm Steffen , Dowe Thomas , Wilkes Edmund H. , Chakravarty Probir , Thompson Richard , Topping Joanne , Cutillas Pedro R. , Lockley Michelle , Serody Jonathan S. , Capasso Melania , Balkwill Frances R.
Published: April 2023

Mean age, disease stage and treatment of the patients used to analyse the CD20 infiltrate of HGSOC metastases by IHC
fig.S2new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

Figure S2 show additional H&E and IHC images and data on mOS14 cell line
Table S2-S3-S4 from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

lists of differentially expressed genes
Table S1 from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

list of primers
Supplemental Figures 7-8 from Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Authors: Kalbasi Anusha , Komar Chad , Tooker Graham M. , Liu Mingen , Lee Jae W. , Gladney Whitney L. , Ben-Josef Edgar , Beatty Gregory L.
Published: April 2023

Supplemental Figure 7: Neutralization of CCL2 delays tumor growth in vivo; Supplemental Figure 8: CCR2 is expressed by a subset of CD45+ leukocytes in tumors
Fig.S5 new from Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Authors: Ratti Chiara , Botti Laura , Cancila Valeria , Galvan Silvia , Torselli Ilaria , Garofalo Cecilia , Manara Maria Cristina , Bongiovanni Lucia , Valenti Cesare F. , Burocchi Alessia , Parenza Mariella , Cappetti Barbara , Sangaletti Sabina , Tripodo Claudio , Scotlandi Katia , Colombo Mario P. , Chiodoni Claudia
Published: April 2023

Figure S5 shows vulcano plots from immune panel results and qPCR validation of specific genes
Supplementary information from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Authors: Xu Xiaowei , De Angelis Carmine , Burke Kathleen A. , Nardone Agostina , Hu Huizhong , Qin Lanfang , Veeraraghavan Jamunarani , Sethunath Vidyalakshmi , Heiser Laura M. , Wang Nicholas , Ng Charlotte K.Y. , Chen Edward S. , Renwick Alexander , Wang Tao , Nanda Sarmistha , Shea Martin , Mitchell Tamika , Rajendran Mahitha , Waters Ian , Zabransky Daniel J. , Scott Kenneth L. , Gutierrez Carolina , Nagi Chandandeep , Geyer Felipe C. , Chamness Gary C. , Park Ben H. , Shaw Chad A. , Hilsenbeck Susan G. , Rimawi Mothaffar F. , Gray Joe W. , Weigelt Britta , Reis-Filho Jorge S. , Osborne C. Kent , Schiff Rachel
Published: April 2023

supplementary methods and figure legends
Table S1-S7 from The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis
Authors: Xu Lei , Mao Xueying , Guo Tianyu , Chan Pui Ying , Shaw Greg , Hines John , Stankiewicz Elzbieta , Wang Yuqin , Oliver R. Tim D. , Ahmad Amar Sabri , Berney Daniel , Shamash Jonathan , Lu Yong-Jie
Published: April 2023

Supplementary Table 1-7. Table S1 Clinical characteristics and CTC/BigNeg cell count for all patients; Table S2 Summary of CTC FISH results in 12 prostate cancer patients and leukocyte signals from controls and patients; Table S3 Proportion of detected genetic changes in sub-populations of cells; Table S4 Clinical features of CTC-score positive and negative patients; Table S5 The number of subtype CTCs in different clinical feature groups; Table S6 ROC curves to predict metastases by CTC counts and PSA level; Table S7 The comparison of sensitivity and specificity to predict metastasis using PSA and CRS.
Table S5 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Significantly Differentially Expressed miRNAs between UCN and UC
Table S1 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Patient demographics and disease specific characteristics.
Supplemental Figure 4 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

FaDu-mock and FaDu-SMAD4 cells were serum starved for 24 hours and then incubated with DMSO or JNK inhibitor (SP600125) for 24 hours. Cell lysates were analyzed by (A) western blot for SMAD4, total and phosphorylated JNK (T183/Y185), and GAPDH as a loading control. (B) AlamarBlue assay measuring cell viability with JNKi or DMSO treatment for 48 hours. (C) Matrigel colony growth assay with 5uM JNK inhibitor for 7 days. FaDu-mock and FaDu-SMAD4 cells were serum starved and then incubated with either DMSO or MEK inhibitor (U0126) for 24 hours. Cell lysates were analyzed by (D) western blot for SMAD4, total and phosphorylated MAPK (T202/Y204), and GAPDH as a loading control. (E) AlamarBlue assay measuring cell viability with MEKi or DMSO treatment for 48 hours. (F) Clonogenic survival in response to 5uM MEKi was examined by the Matrigel colony growth assay for 7 days.
Figure S1 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

Representative SMAD4 IHC, FaDu negative control, SCC25/SCC61 positive control.
Supplementary Tables 1-5 from Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Authors: Parkhurst Maria , Gros Alena , Pasetto Anna , Prickett Todd , Crystal Jessica S. , Robbins Paul , Rosenberg Steven A.
Published: April 2023

These tables contain details describing mutations identified by whole exome and RNA sequencing, tandem mini-gene constructs, and HLA peptide binding predictions
SUPPLEMENTAL MATERIALS from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Authors: Segal Neil H. , Logan Theodore F. , Hodi F. Stephen , McDermott David , Melero Ignacio , Hamid Omid , Schmidt Henrik , Robert Caroline , Chiarion-Sileni Vanna , Ascierto Paolo A. , Maio Michele , Urba Walter J. , Gangadhar Tara C. , Suryawanshi Satyendra , Neely Jaclyn , Jure-Kunkel Maria , Krishnan Suba , Kohrt Holbrook , Sznol Mario , Levy Ronald
Published: April 2023

Methods Supplement Supplementary Table 1. Patients Included in E-R Analysis Supplementary Table 2. Patients From Studies -006 and -011 Not Included in ER Analysis Supplementary Fig 1. Serum concentration:time profile of urelumab across the dose range evaluated (0.1 to 15 mg/kg) Supplementary Fig 2. Induction of a range of IFN-response genes by urelumab 0.1 mg/kg
Figure S7 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

Overexpression of MDM4 in 1q32.1 normal EC cell lines.
Supplementary Table 4 from Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Tarlock Katherine , Alonzo Todd A. , Loken Michael R. , Gerbing Robert B. , Ries Rhonda E. , Aplenc Richard , Sung Lillian , Raimondi Susana C. , Hirsch Betsy A. , Kahwash Samir B. , McKenney Amy , Kolb E. Anders , Gamis Alan S. , Meshinchi Soheil
Published: April 2023

Supplementary Table 4. Correlation with outcome for patients with low vs. high FLT3 expression according to mRNA transcript expression or cell surface expression detected by MDF.
Supplemental Table 1 from Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Authors: Lochmann Timothy L. , Floros Konstantinos V. , Naseri Mitra , Powell Krista M. , Cook Wade , March Ryan J. , Stein Giovanna T. , Greninger Patricia , Maves Yuki Kato , Saunders Laura R. , Dylla Scott J. , Costa Carlotta , Boikos Sosipatros A. , Leverson Joel D. , Souers Andrew J. , Krystal Geoffrey W. , Harada Hisashi , Benes Cyril H. , Faber Anthony C.
Published: April 2023

Supplemental Table 1 shows venetoclax screen data (AUC and IC50) across 791 solid tumor cell lines.
Figure S4 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Authors: Ramanathan Ramesh K. , Korn Ronald L. , Raghunand Natarajan , Sachdev Jasgit C. , Newbold Ronald G. , Jameson Gayle , Fetterly Gerald J. , Prey Joshua , Klinz Stephan G. , Kim Jaeyeon , Cain Jason , Hendriks Bart S. , Drummond Daryl C. , Bayever Eliel , Fitzgerald Jonathan B.
Published: April 2023

Additional Prussian blue and CD68 staining in a tumor core biopsy after FMX dosing. (A, B) Serial tumor sections from formalin-fixed, paraffin-embedded biopsies of liver lesions were stained for (A) FMX (Prussian blue) and (B) macrophages (CD68). FMX deposition is detectable primarily in vascular-accessible macrophages in stromal areas surrounding tumor lesions.
Supplementary Tables from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

Pathological and Clinical Characteristics of Patients with Adrenocortical Carcinoma in the Training Set, Pathological and Clinical Characteristics of Patients with Adrenocortical Carcinoma in the Validation Set, Summary Findings of Features, Features Identified by Phase of Chromatography and Ionization
Table S2 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

Different T cell subpopulations contained in the CD45RA- compartment
Supplementary Table S3 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Major pathways significantly associated with the top filtered differentially expressed genes regulated by vorinostat or in combination with AZD1775 identified by the GO enrichment and IP analyses.
Table S4 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Characteristics of the patients who underwent radical nephroureterectomy for UTUC.
Figure S4 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

HSPC-derived DCs generated in vitro display DC phenotype and function.
Supplementary Fig 7 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 7
Supplementary Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Authors: Burton Jenna H. , Mazcko Christina , LeBlanc Amy , Covey Joseph M. , Ji Jiuping , Kinders Robert J. , Parchment Ralph E. , Khanna Chand , Paoloni Melissa , Lana Sue , Weishaar Kristen , London Cheryl , Kisseberth William , Krick Erika , Vail David , Childress Michael , Bryan Jeffrey N. , Barber Lisa , Ehrhart E.J. , Kent Michael , Fan Timothy , Kow Kelvin , Northup Nicole , Wilson-Robles Heather , Tomaszewski Joseph , Holleran Julianne L. , Muzzio Miguel , Eiseman Julie , Beumer Jan H. , Doroshow James H. , Pommier Yves
Published: April 2023

All supplementary files together